A few questions I still have: What caused the B
Post# of 72446
(Total Views: 318)
Posted On: 05/09/2018 1:39:44 PM
A few questions I still have:
What caused the B-OM trial to have such outrageously high placebo cure rate? It should have been below 10%. The only cause I can believe is that some person(s) screwed with the administration of the trial. Hard to believe, but placebo so out of line it had to be the hand of humans that caused the difference.
A statement I read said that Brilacidin was 100 times as potent as natural defensin proteins and 1000 times as selective. Now how can Brilacidin differentiate between good/bad bacteria or viruses? Does it kill everything as was noted in the first PolyMedix B clinical trial when the dose level had to be scaled back or is it selective as above statement indicated (and I am not sure but thought the statement came from mgt)?
Anybody else believe there is far more to the EVONIK deal than them strictly being a source for our sachet B-OM packets?
Have been expecting next week to be the big P2b news release target date (just a gut feeling from latter half of March) but now not so sure. Just hope it doesn't drag on much longer. If it does, I believe we may get a deal PR prior to the Prurisol PR. Expecting great news.
Hope we get some news re FDA advancements for various matters in the next 4 weeks or so to keep positive news flowing.
As with most here, SP at this time irrelevant to my concerns.
What caused the B-OM trial to have such outrageously high placebo cure rate? It should have been below 10%. The only cause I can believe is that some person(s) screwed with the administration of the trial. Hard to believe, but placebo so out of line it had to be the hand of humans that caused the difference.
A statement I read said that Brilacidin was 100 times as potent as natural defensin proteins and 1000 times as selective. Now how can Brilacidin differentiate between good/bad bacteria or viruses? Does it kill everything as was noted in the first PolyMedix B clinical trial when the dose level had to be scaled back or is it selective as above statement indicated (and I am not sure but thought the statement came from mgt)?
Anybody else believe there is far more to the EVONIK deal than them strictly being a source for our sachet B-OM packets?
Have been expecting next week to be the big P2b news release target date (just a gut feeling from latter half of March) but now not so sure. Just hope it doesn't drag on much longer. If it does, I believe we may get a deal PR prior to the Prurisol PR. Expecting great news.
Hope we get some news re FDA advancements for various matters in the next 4 weeks or so to keep positive news flowing.
As with most here, SP at this time irrelevant to my concerns.
(2)
(0)